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The oestrogen receptor alpha-regulated lncRNA
NEAT1 is a critical modulator of prostate cancer
Dimple Chakravarty1,2, Andrea Sboner1,2,3, Sujit S. Nair4, Eugenia Giannopoulou5,6, Ruohan Li7, Sven Hennig8,
Juan Miguel Mosquera1,2, Jonathan Pauwels1, Kyung Park1, Myriam Kossai1,2, Theresa Y. MacDonald1,
Jacqueline Fontugne1,2, Nicholas Erho9, Ismael A. Vergara9, Mercedeh Ghadessi9, Elai Davicioni9,
Robert B. Jenkins10, Nallasivam Palanisamy11,12, Zhengming Chen13, Shinichi Nakagawa14, Tetsuro Hirose15,
Neil H. Bander16, Himisha Beltran1,2, Archa H. Fox7, Olivier Elemento2,3 & Mark A. Rubin1,2
The androgen receptor (AR) plays a central role in establishing an oncogenic cascade that
drives prostate cancer progression. Some prostate cancers escape androgen dependence and
are often associated with an aggressive phenotype. The oestrogen receptor alpha (ERa) is
expressed in prostate cancers, independent of AR status. However, the role of ERa remains
elusive. Using a combination of chromatin immunoprecipitation (ChIP) and RNA-sequencing
data, we identiﬁed an ERa-speciﬁc non-coding transcriptome signature. Among putatively
ERa-regulated intergenic long non-coding RNAs (lncRNAs), we identiﬁed nuclear enriched
abundant transcript 1 (NEAT1) as the most signiﬁcantly overexpressed lncRNA in prostate
cancer. Analysis of two large clinical cohorts also revealed that NEAT1 expression is asso-
ciated with prostate cancer progression. Prostate cancer cells expressing high levels of NEAT1
were recalcitrant to androgen or AR antagonists. Finally, we provide evidence that NEAT1
drives oncogenic growth by altering the epigenetic landscape of target gene promoters to
favour transcription.
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S
teroid receptors are key transducers of hormone signalling
and control a wide spectrum of tissue-speciﬁc functions that
are critical for the physiological homeostasis of reproductive
organs. Aberrant or deregulated expressions of steroid nuclear
receptors are often associated with cancer progression and have
been a major target for therapeutic intervention. The androgen
receptor (AR) plays a central role in the progression of prostate
cancer1. Androgen ablation is highly effective in treating
metastatic prostate cancer, although resistance inevitably
develops leading to castrate-resistant prostate cancer (CRPC).
Most cases of CRPC remain dependent on AR signalling, which
has led to the clinical development and recent approval of potent
AR-targeted therapies for CRPC (that is, abiraterone and
enzalutamide)2,3. However, similar to ﬁrst-generation anti-
androgen therapies, patients develop resistance to these second-
generation hormonal therapies. How CRPC tumours bypass AR
signalling is emerging as a signiﬁcant area of investigation. Many
view co-targeting therapies as an important next step to
managing the inevitable emergence of resistance to single-agent
treatments, but critical to co-targeting is the identiﬁcation of
other biological pathways that drive disease progression and the
development of strategies that can target judgmental pathways.
In CRPC, cross-talk between oestrogen- and androgen-
signalling pathways may present an opportunity for clinical
intervention. Oestrogen receptor (ER) signalling through ERa
increases with prostate cancer progression4–6 and can
drive important oncogenic events, including TMPRSS2-ERG
expression7. Although ERa signalling has been extensively
studied in breast cancer8–10, our understanding of the potential
impact of this nuclear receptor on prostate physiology is less
clear. Nevertheless, the connection is a particularly intriguing
concept given that most cases of prostate cancer arise in the sixth
decade of life, a time when testosterone levels are decreasing and
oestrogens are increasing in men. Mouse models suggest that
antagonism of ERa may diminish prostate carcinogenesis4.
We posit that ERa is an important alternate signalling pathway
for the transcriptional regulation of prostate cancer, allowing
refractory disease to bypass androgen/AR signalling. Herein, we
provide experimental evidence to support this hypothesis and
demonstrate a functional specialization and distinct genomic role of
this nuclear receptor in prostate cancer, with signiﬁcant implications
for prognosis and management. We show that ERa is recruited to
both coding and non-coding regions of the prostate genome and
orchestrates expression of non-coding regulatory RNAs.
We identiﬁed nuclear enriched abundant transcript 1 (NEAT1)
long non-coding RNA (lncRNA) as a potential target of ERa and
as an important mediator for maintenance of prostate cancer.
NEAT1 functions as a transcriptional regulator and contributes to
a cancer-favourable transcriptome, thereby promoting tumor-
igenesis in experimental animal models. Our analysis of the
transcriptional role of NEAT1 identiﬁed functions beyond its
previously characterized role in maintaining the integrity of
subnuclear organelles called paraspeckles5. We demonstrate that
NEAT1 is recruited to the chromatin of well-characterized
prostate cancer genes and contributes to an epigenetic ‘on’
state. Analysis of two large clinical cohorts nominated NEAT1 as
a novel biomarker of disease progression. Given its signiﬁcance
within the ERa signalling pathway, we propose that targeting
NEAT1 might represent a novel and important therapeutic
strategy for the treatment of prostate cancer.
Results
ERa in transcriptional regulation of prostate cancer. To
elucidate the role of ERa in prostate cancer, we analysed ERa
protein and transcript levels in a panel of prostate cancer cell lines
(n¼ 5) and in a cohort of matched benign prostate tissue (n¼ 14)
and prostate adenocarcinoma (PCa) (n¼ 14), respectively. We
observed that ERa was signiﬁcantly upregulated (P¼ 0.03) in
prostate tumours compared with benign tissues (Fig. 1a). To
determine the clinical relevance of ERa in prostate cancer, we
performed immunohistochemistry using a tissue microarray
composed of tissue cores from 64 samples of benign prostate
tissue, 16 high-grade prostate intraepithelial neoplasia, 292 PCa,
and 42 neuroendocrine prostate cancer (NEPC). Representative
photomicrographs are depicted in Supplementary Fig. 1a.
Although benign prostate had only low expression levels of ERa,
ERa was detected in adenocarcinoma and the adjacent high-grade
prostate intraepithelial neoplasia through focal nuclear and
cytoplasmic staining (Supplementary Fig. 1a). ERa is over-
expressed in a signiﬁcant number of prostate cancer cohorts. It
was also found to be overexpressed in prostate cancers with high
Gleason score (GS) compared with those with low GS as well as in
those with tumour recurrence when analysed via the Oncomine6
database (Fig. 1b)7–22. Analysis of subcellular distribution in
prostate cancer cell lines revealed signiﬁcant nuclear distribution
of ERa in all cell lines tested (Supplementary Fig. 1b). ERa
protein levels were similar in both AR-positive LnCaP and VCaP
cells (Fig. 1a, inset). We used parental VCaP and the ERa-positive
prostate cancer cell line NCI-H660 as model cell lines to further
explore and delineate the speciﬁc contribution of ERa to prostate
cancer. A ligand-dependent modulation of invasive potential was
observed in VCaP cells on oestrogen (E2) treatment (Fig. 1c).
These results suggest that a functionally relevant, ligand-
dependent ERa signalling pathway is active in prostate cancer
cell lines.
To further understand the impact of ERa, we generated VCaP
cells that overexpress ERa (VCaP ERa). Stable expression of ERa
was conﬁrmed by western blotting (Supplementary Fig. 1c).
VCaP ERa exhibited signiﬁcantly higher invasive potential than
VCaP parental cells or the vector control cells (Fig. 1c).
Intriguingly, the noted effects of ERa overexpression were
independent of AR status, as experimental silencing of AR in
VCaP ERa cells (Supplementary Fig. 1c) did not compromise the
increased invasive potential of E2-treated VCaP ERa cells
(Fig. 1c). These data suggest that prostate cancer cells can use
alternate nuclear receptor signalling (for example, ERa signalling)
to propagate, and understanding these mechanisms will help
discern the complete spectrum of key regulators of prostate
cancer progression.
Studies have established ERa’s dominant role in transcriptional
regulation of target genes in breast cancer23,24. Likewise, high
nuclear levels of ERa in prostate cancer cells (Supplementary
Fig. 1b) and their direct association with chromatin implicate
ERa in the transcriptional regulation of this cancer, as well. We
used ERa chromatin immunoprecipitation coupled with high-
throughput sequencing (ChIP-seq) in VCaP cells, with and
without E2 treatment, and also in VCaP ERa and NCI-H660 cells
with E2 treatment to investigate the underlying mechanisms by
which ERa might drive a transcriptional programme in prostate
cancer. The majority of ERa-binding sites were cell speciﬁc
(Supplementary Fig. 1d). Analysis of the ChIP-seq data for ERa
in NCI-H660 and VCaP ERa cells revealed that 64.9% of ERa
binding occurred within intergenic regions of the prostate
genome. This fraction is higher than the expected fraction if
peaks were randomly distributed across the genome (P¼ 3e 05)
(Supplementary Fig. 1e).
Using publicly available data sets25, we found that 28% of the
intergenic ERa-binding sites in the prostate cancer genome (from
VCaP ERa and NCI-H660 cell lines) overlapped with the active
histone marks trimethylated lysine 4 of histone H3 (H3K4me3)
and trimethylated lysine 36 of histone H3 (H3K36me3)
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(Po1e 7). On the other hand, 20.7% of those sites overlapped
with histone marks typical of inactive chromatin, such as
trimethylated lysine 9 of histone H3 or trimethylated lysine 27
of histone H3. To prioritize experimental validation of ERa
targets, we ranked the peaks according to the average P-value
determined by the peak-calling algorithm ChIPSeeqer26 and
selected the highest ranking peaks for further analysis. We
analysed recruitment of endogenous ERa to the top 11 binding
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Figure 1 | ERa plays a distinct role in prostate cancer. (a) ERa is upregulated in prostate cancer compared with matched benign controls. Waterfall plots
depict the qRT-PCR expression levels of ERa mRNA in an independent cohort of benign (n¼ 14) and PCa (n¼ 14). (inset A) The expression of ERa in
different prostate cancer cell lines was determined by western blotting and compared with MCF7, a breast cancer cell line. (b) Analysis of ERa expression
in Oncomine public data sets of normal versus prostate cancer and advanced disease. (c) Invasion of VCaP and VCaP ERa cells analysed 48 h post
treatment with vehicle control or E2 (10 nM) in the presence of control or AR-siRNA. Results are expressed as the mean±s.d. of three independent
experiments. Student’s t-test was performed for comparisons (% Invasion) between  E2 and þ E2 conditions for ERa, ERa-Ctrl siRNA and AR-siRNA, and
**Po0.01 were considered statistically signiﬁcant. (d) Recruitment of endogenous ERa to target gene chromatin was analysed in VCaP cells with or without
E2 treatment. Results are expressed as the percentage of input of two independent experiments. Error bars represent the range of data. (e) Computational
pipeline for identiﬁcation of ERa-regulated lncRNAs upregulated in prostate cancer: a schematic overview of the methodology employed to identify ERa-
regulated lncRNAs that are differentially expressed between benign versus prostate cancer and prostate cancer versus NEPC. (f) Box plots show expression
levels of the top three ERa-regulated lncRNAs from 26 benign and 40 PCa cases, with ideogram depicting their chromosomal position. Waterfall plots
depict the qRT-PCR expression levels on an independent cohort of benign (n¼ 14) and PCa (n¼ 14) of the three nominated lncRNAs: NEAT1, NR_024490
and FR349599.
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sites in parental VCaP cells (Fig. 1d), providing an experimental
validation of the ChIP-seq data. A signiﬁcantly higher
recruitment of ERa was evident at the binding sites compared
with control IgG.
Given the enhanced recruitment of ERa to intergenic regions
of the prostate genome, we evaluated the likelihood that ERa
might inﬂuence transcriptional output and thereby the reper-
toire of non-coding RNA in the context of prostate cancer. We
thus analysed the abundance of non-coding transcripts in RNA-
seq data derived from a cohort of 73 prostate tissues, which
included 26 benign prostate samples, 40 PCa and 7 NEPC
(Supplementary Dataset 1), focusing our analysis on 6,850
intergenic lncRNAs out of 12,143 known lncRNAs (see
Supplementary Methods). We identiﬁed 1,314 and 1,399
intergenic lncRNAs that are differentially expressed between
benign and PCa, and between PCa and NEPC, respectively (false
discovery rate o0.01). We identiﬁed 140 intergenic lncRNAs
putatively regulated by ERa (Fig. 1e and Supplementary Dataset 2).
An analysis of AR-binding sites25 identiﬁed 98 lncRNAs that
have an AR-binding site within the promoter. This supported the
view that ERa might signiﬁcantly inﬂuence the non-coding
transcriptome in prostate cancer. Using the RNA-seq data on
VCaP and VCaP ERa cell lines to validate the expression levels of
the top differentially expressed ERa-regulated lncRNAs, we
selected six potential candidate lncRNAs that had higher
expression in VCaP ERa compared with VCaP. We used
quantitative real-time PCR (qRT–PCR) to validate expression
for these six ERa-regulated lncRNAs in VCaP and VCaP ERa-
expressing cell lines (Supplementary Fig. 1f). Expression of three
of these lncRNAs was further determined in a cohort of 28
matched benign and prostate cancer samples, conﬁrming
upregulation of these three nominated lncRNAs in prostate
cancer compared with benign prostate (Fig. 1f). Taken together,
these analyses indicate that ERa is a transcriptional regulator of
the non-coding transcriptome in prostate cancer.
Among the putatively ERa-regulated intergenic lncRNAs, we
identiﬁed NEAT1 as the most signiﬁcantly overexpressed lncRNA
in prostate cancer versus benign prostate in our patient cohort
(73 samples) (Fig. 1f and Supplementary Dataset 2). The NEAT1
gene is located on chromosome 11q13.1 and produces two RNA
isoforms that overlap completely at the 50-end. The shorter
isoform (hereafter abbreviated as NEAT1/NEAT1_1) is 3.7 kb in
length and more abundant than the longer, 23 kb isoform
(NEAT1_2)27. NEAT1 lncRNA is essential for the formation of
subnuclear bodies called paraspeckles27, and although both
isoforms localize to paraspeckles, their physiological role in
prostate cancer remains unknown.
ERa-regulated NEAT1 lncRNA is upregulated in prostate
cancer. In the Oncomine database, we observed signiﬁcant
overexpression of NEAT1 lncRNA in several prostate cancer data
sets (normal versus cancer) and aggressive prostate cancer
(Fig. 2a)7,10–22,28–31. We ﬁrst conﬁrmed that ampliﬁcation of
chromosome 11q (where NEAT1 resides) was not seen across 109
adenocarcinoma cases32, eliminating chromosome 11q13.1
ampliﬁcation as an explanation for high NEAT1 expression
(Supplementary Fig. 2a)33,34. The expression of NEAT1 in two
radical prostatectomy cohorts with long-term clinical follow-up
from the Mayo Clinic35,36 was measured using Affymetrix HuEx
microarrays (see Methods). Supplementary Table 1 contains the
patient characteristics of the data sets. NEAT1’s expression
ranked in the 99th percentile of all genes on the microarray
(Fig. 2b). We determined levels of NEAT1 by RNA in situ
hybridization (ISH) in a tissue microarray that included 16
benign prostate tissues, 21 PCa, 12 PCa with neuroendocrine
differentiation and 7 NEPC cases. NEAT1 was found to be highly
expressed in prostate cancer compared with that in benign tissue
(Supplementary Fig. 2b).
We observed that in a panel of prostate cancer cell lines, ERa
overexpression and E2 treatment upregulated NEAT1 transcript
levels in a time-dependent manner (Fig. 2c). In DU145, an ERG-
negative cell line37, E2/ERa signalling was intact (Fig. 2c),
supporting an ERG-independent phenomenon. Following ERa
overexpression, we also recorded an increase in expression of the
long isoform NEAT1_2 (Supplementary Fig. 2c). This was not
surprising as both isoforms of NEAT1 are driven by the same
promoter38. The preferential upregulation and increase in the
NEAT1 long form alone is not well understood and is not further
addressed in this study. Interestingly, knockdown of ERb did not
alter NEAT1 levels, suggesting that NEAT1 regulation is speciﬁc
for ERa (Supplementary Fig. 2d).
NEAT1 was originally identiﬁed localized to subnuclear
organelles called paraspeckles that are free of chromatin and
function as repositories of edited RNA and a number of nuclear
RNA-binding proteins5. Loss of NEAT1 dramatically reduces the
formation of paraspeckles. Treatment of VCaP cells with E2
resulted in re-distribution of NEAT1 from paraspeckles to an
enhanced distribution throughout the nucleus (Supplementary
Fig. 2e).
We inspected our ERa ChIP-seq data in VCaP ERa and NCI-
H660 cells, and identiﬁed two ERa-binding sites on the NEAT1
promoter (Fig. 2d). Analysis of chromatin marks using ChIP-seq
data sets for histone marks25 revealed the presence of active
histone marks H3 Acetyl K9 and H3K4me3 in the promoter
region of NEAT1, while H3K36Me3 marks were abundant in the
Figure 2 | ERa regulated NEAT1 lncRNA is upregulated in prostate cancer. (a) NEAT1 is overexpressed in various prostate data sets (Oncomine).
(b) Distribution of the median expression of all genes (core transcript clusters) on the Human Exon 1.0 STarray in the pooled Mayo Clinic cohort (n¼ 594).
NEAT1’s expression ranks in the 99th percentile of all genes on the array. (c) Expression of NEAT1 with/without ERa overexpression and E2 treatment
(10 nM) at different time points in a panel of prostate cancer cell lines. Results are expressed as the mean±s.d. of three independent experiments.
(d) View of NEAT1 genomic location indicates presence of two ERa-binding sites in the promoter region. Read coverage tracks derived from RNA-
sequencing data indicates a higher abundance of NEAT1 transcripts in PCa compared with benign tumours in three representative cases. The ﬁgure also
reports the ChIP-sequencing coverage tracks for ERa (VCaP ERa, VCaP and input DNA as control). The bottom panel shows the binding sites of ERa, AR
(GEO Accession GSM353651-tissue AR (ref. 25)), Ace-H3, H3K4me3 and H3K36me3 in VCaP cell line (GEO Accession GSM353629, GSM353620 and
GSM353624 (ref. 25)), respectively. (e) Chromatin immunoprecipitation followed by qPCR to study ERa recruitment to NEAT1 promoter in VCaP cells
with/without E2 treatment (10 nM) was performed with primers spanning the binding regions identiﬁed by ERa ChIP-seq data. Primers for nonspeciﬁc
region were used as negative control for ChIP studies. Results are expressed as percentage of input from two independent experiments. Vertical error bars
represent the range of data. (f) Luciferase-based promoter reporter assays was used to analyse effect of ERa and/or AR on ERE-Luc promoter in VCaP
cells. Cells were transiently transfected with the (ERE)3-SV40-luc reporter plasmid and ERa, or AR-treated with/without E2 or R1881 (1 nM) for 48 h.
Results are expressed as the mean±s.d calculated from three independent experiments. (g) Luciferase-based promoter reporter assays were used to
analyse NEAT1 promoter activity following ERa expression  /þ E2 (10 nM) for 24 h. Results are expressed as the means±s.d. calculated from three
independent experiments. Student’s t-test was performed for comparisons where indicated, and *Po0.05 and **Po0.01 were considered statistically
signiﬁcant.
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gene body (Fig. 2d). A recent study revealed that bivalent
H3K4Me3 and H3K36Me3 marks are indicators of functional
transcriptional loci from the non-coding genome39. ERa
recruitment to speciﬁc regions of the NEAT1 promoter was
independently validated by ERa ChIP in VCaP, VCaP ERa and
NCI-H660 cells (Fig. 2e and Supplementary Fig. 2f,g) using
speciﬁc primers encompassing ERa-binding sites in the NEAT1
promoter. We found that a functional oestrogen/ERa signalling
pathway was active in VCaP cells, as determined by reporter-
based estrogen response element (ERE) luciferase assays in VCaP
cells, with ERa and AR overexpression, and E2 or R1881
treatment, respectively, for 48 h (Fig. 2f). To further test whether
ERa is required for NEAT1 transcriptional activation, we
generated luciferase promoter reporter constructs with both
ERa-binding sites upstream of the luciferase-coding region.
Luciferase reporter assays in VCaP cells conﬁrmed that NEAT1
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promoter activity was upregulated in an ERa-dependent manner
and further enhanced with E2 treatment (Fig. 2g).
ERa and NEAT1 regulate several prostate cancer genes. We
next sought to understand the physiological role of NEAT1 and
to determine the downstream targets of the ERa-NEAT1 axis in
prostate cancer. We were particularly interested in identifying
genes signiﬁcantly deregulated in prostate cancer and positively
correlated with ERa and NEAT1 expression. Transcriptome
sequencing of VCaP and VCaP ERa cells and pairwise compar-
ison revealed 588 genes to be upregulated in VCaP ERa cells
(log2-fold change 42) (Supplementary Dataset 3 and Fig. 3a).
We performed a comparative analysis of this 588 gene signature
using Oncomine concept analysis. We focused on data sets from
prostate cancer studies that included both prostate tumour and
benign prostate tissues. The analysis revealed that the ERa gene
signature was signiﬁcantly upregulated in a number of prostate
cancer data sets, but was downregulated in other non-prostate
data sets, indicating that ERa regulates prostate cancer-speciﬁc
genes (Fig. 3b and Supplementary Dataset 4).
To validate whether ERa targets identiﬁed by in silico analysis
are dependent on cellular levels of ERa, we experimentally
silenced ERa in VCaP cells using an small interfering RNA
(siRNA) approach and determined transcript levels of ten target
genes using qRT–PCR. The target genes selected for validation
were those genes that demonstrated the highest log2-fold
difference in VCaP and VCaP ERa cells. Results indicated that
messenger RNA levels of the target genes selected were dependent
on ERa (Fig. 3c), suggesting a distinct contribution of ERa in
determining the transcriptional programme.
NEAT1 is a downstream target in the ERa signalling pathway.
After determining an ERa signature, we next investigated the
potential role of NEAT1. Interestingly, knockout of NEAT1
compromised the expression of ERa target genes, suggesting that
NEAT1 is not only a downstream target but also a mediator of ERa
signalling in prostate cancer cells (Fig. 3d). To evaluate this further
and to determine whether a functional synergy between ERa and
NEAT1 pathways exists in prostate cancer cells, we performed
RNA-seq of vector control and NEAT1-overexpressing VCaP cells
to determine a NEAT1 signature. To achieve this, we limited our
analysis to genes that were upregulated four-fold in NEAT1-
expressing cells (Supplementary Dataset 5). Interestingly, the
NEAT1 signature showed a strong correlation with the ERa sig-
nature genes (q¼ 1.90E 120). Analysis of the top 1,000 genes of
the NEAT1 signature revealed that this signature is upregulated in
prostate cancer data sets when compared with other cancer data
sets (Fig. 3e and Supplementary Dataset 4). Furthermore, the
NEAT1 signature was also upregulated in all prostate cancer data
sets (comparing benign versus PCa; odds ratio 42.0 and
Po1 10 6) (Supplementary Fig. 3a).
We also queried Oncomine prostate data sets to identify genes
whose mRNA levels correlate with those of NEAT1 (correlation
coefﬁcient 40.5). We compared this gene list with the ERa
signature genes from our analysis in Fig. 3a and identiﬁed 155
genes in common. These 155 genes were also found to be
upregulated in all prostate cancer data sets compared with other
cancer data sets (only normal versus cancer data sets were
considered; odds ratio 43.0 and Po1 10 6) (Supplementary
Dataset 4 and Supplementary Fig. 3b).
To determine whether the genes identiﬁed by in silico analysis
are indeed inﬂuenced by NEAT1, we silenced NEAT1 in VCaP
cells and determined transcript levels of potential target genes
using qRT–PCR. We selected the top ten genes that were
signiﬁcantly correlated to NEAT1 expression across all prostate
cancer concepts. As expected, mRNA levels of these selected
target genes were indeed dependent on NEAT1, further
conﬁrming a deﬁnite role of NEAT1 in the transcriptional
programme (Fig. 4a). In addition to cell lines, we also determined
transcript levels of these ERa-NEAT1 signature-selected genes in
a small patient cohort (n¼ 26) of 13 matched benign and PCa,
respectively. We observed that relative mRNA levels of these
NEAT1-ERa signature-selected genes revealed signiﬁcant upre-
gulation in prostate cancer (Fig. 4b). We computed the log2-fold
change of expression levels using the 13 paired tumour/benign
samples for NEAT1 and for these selected genes. We then
correlated the fold change values and observed a moderate-to-
strong correlation between NEAT1 and the associated genes in
clinical samples (Fig. 4c). Among these seven genes, prostate-
speciﬁc membrane antigen (PSMA) and alpha-methylacyl-CoA
racemase (AMACR) are well-known diagnostic and, in the case of
PSMA, prognostic markers of prostate cancer progression40–44.
Furthermore, knocking down ERb did not alter expression of key
signature genes in LnCaP, PC3, VCaP and NCI-H660 cells
(Supplementary Fig. 3c), suggesting a non-redundant regulatory
role for ERa.
NEAT1 and chromatin regulation. To study the potential role of
NEAT1 in regulation of target genes in vivo, we performed
luciferase reporter assays using PSMA-luc as a candidate NEAT1
target. NEAT1 induced robust activation of the PSMA promoter
in PC3 cells (Fig. 5a) and VCaP cells (Fig. 5b). These results
prompted us to investigate whether NEAT1 is recruited to
chromatin of target genes. We used the chromatin isolation by
RNA puriﬁcation (ChIRP) approach45 to pull down endogenous
NEAT1 from VCaP cells. Analysis of the ChIRP data revealed
that NEAT1 is recruited to the PSMA promoter, but not the
downstream exon 1 (Fig. 5c). In addition to PSMA, we also
tested NEAT1 recruitment to other target genes described in
Figs 3c and 4a, and observed that in addition to PSMA, NEAT1
was also recruited to the promoter region of GJB1 (Supplementary
Fig. 4a). This suggests that NEAT1 transcriptionally regulates a
Figure 3 | NEAT1 ERa signature correlates with prostate cancer. (a) Scatter plots for gene expression levels in VCaP ERa compared with VCaP cell lines.
(b) Five hundred and eighty-eight genes that are overexpressed in VCaP ERa (log2-fold change 42) were used for Oncomine concept analysis across
different cancer data sets (see Methods for detail). (c) qRT–PCR analysis of relative mRNA levels of ERa target genes in VCaP cells with knockout of ERa
with and without E2 treatment. The target genes selected for validation are the ones that had the highest log2-fold difference in VCaP and VCaP ERa cell
lines. Results are expressed as the mean±s.d. calculated from three independent experiments. Student’s t-test was performed (as indicated) for
comparisons between  E2 and þ E2 conditions for Ctrl siRNA and ERa-siRNA transfections, and *Po0.05 and **Po0.01 were considered statistically
signiﬁcant. A representative example is shown for ERG target expression. (d) qRT–PCR analysis of ERa target genes in VCaP cells with ERa overexpression
and NEAT1 knockout with and without E2 treatment. Results are expressed as the mean±s.d. calculated from three independent experiments. Student’s
t-test was performed for comparisons between  E2 and þ E2 conditions for scrambled shRNA and NEAT1 shRNA transfections in VCaP and VCaP ERa
cells, and *Po0.05 and **Po0.01 were considered statistically signiﬁcant. A representative example is shown for SPDEF target expression. (e) Network
representation of NEAT1 signature, derived from genes overexpressed in VCaP NEAT1 (NEAT1 signature) cells, across different cancer data sets using
Oncomine concept analysis.
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compendium of genes known to be involved in prostate cancer
progression. We hypothesized that NEAT1 might contribute to
gene transcription by interacting with chromatin-modifying
proteins and/or interacting with histones. Several recent studies
support the view that lncRNAs recruit chromatin-modifying
machinery46–49. To test this hypothesis, we analysed the
chromatin landscape at the PSMA promoter and observed that
NEAT1_1, and not NEAT1_2, facilitated gene transcription by
promoting an active chromatin state (Fig. 5d). Overexpression of
NEAT1_1 signiﬁcantly increased active chromatin marks at the
PSMA promoter (that is, H3K4Me3 and H3AcK9). Of note, ERa
was not signiﬁcantly recruited to the PSMA promoter when
expressed alone. Overexpression of NEAT1_1 resulted in
subsequent recruitment of NEAT1_1 and ERa to the PSMA
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Figure 4 | NEAT1 ERa signature is upregulated in prostate cancer. (a) Relative mRNA levels of genes nominated from analysis in Fig. 3b,e, analysed using
qRT–PCR in parental VCaP cells transfected with scrambled (Sc) and NEAT1 shRNA (N1), respectively, with and without E2 (10 nM) treatment. Results are
expressed as the mean±s.d. calculated from three independent experiments. Student’s t-test was performed for comparisons (relative mRNA levels of
target gene expression) between  E2 and þ E2 conditions for scrambled shRNA and NEAT1 shRNA transfections. A representative example is shown for
ADRB1 and PSMA target expression. *Po0.05 and **Po0.01 were considered statistically signiﬁcant. (b) Validation of expression of the top target NEAT1
ERa signature genes in a small matched patient cohort of 13 benign and 13 PCa, n¼ 26. Results are expressed as the relative mRNA levels tumor/benign
from two independent experiments. Error bars represent the range of data. (c) Heatmap shows the Spearman’s correlation results from b.
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Figure 5 | NEAT1 is a transcriptional regulator. (a,b) Promoter luciferase reporter assay shows that NEAT1 activates PSMA promoter in PC3 and VCaP
cells. Cells were co-transfected with empty vector or PSMA luc and Renilla-luc reporter genes alone or with NEAT1, NEAT1þ ERa and NEAT1þAR.
Luciferase activity was measured 48 h post treatment with E2 (10 nM) or R1881 (1 nM). Results are expressed as the mean±s.d. calculated from three
independent experiments. Student’s t-test was performed for comparisons (relative PSMA–luciferase activity) between  E2 and þ E2 conditions for
vector control, NEAT1 and NEAT1þ ERa transfections in PC3 and VCaP cells. *Po0.05 and **Po0.01 were considered statistically signiﬁcant. (c)
Quantitative analysis of NEAT1 ChIRP in VCaP cells with or without E2 treatment (10 nM). Recruitment proﬁles of NEAT1 to PSMA are shown. Results are
expressed as the percentage of input calculated from two independent experiments. Error bars represent the range of data. Results were reproducible
between representative experiments. **Po0.01 was considered statistically signiﬁcant. (d) Analysis of the chromatin landscape at the PSMA promoter
performed by ChIP in VCaP cells alone or transected with NEAT1, ERa, NEAT1 ERa, NEAT1 ERa NEAT1_1 siRNA and NEAT1 ERa NEAT1_2 siRNA with and
without E2 treatment. qPCR was performed with speciﬁc primers for the PSMA promoter. Results are expressed as the percentage of input calculated from
two independent experiments. Error bars represent the range of data. Results were reproducible between representative experiments. (e) NEAT1 binds to
Histone H3. 20 mer-biotinylated NEAT1 and NR_024490 antisense probes were used to immunoprecipitate NEAT1 and NR_024490 from nuclear lysates
of VCaP cells using streptavidin magnetic beads. Immunoprecipitates from Streptavidin-IP were analysed on 15% gel and probed for Histone H3. NEAT1 is
shown to also bind with active histone H3 modiﬁcations, including H3AcK9 and H3K4Me3.
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promoter. These studies indicate that although NEAT1_1 may
function as a chaperone for ERa and other chromatin-modifying
machinery to target promoters, binding of ERa and/or recruitment
to NEAT1_1 targets is not necessary for transcriptional activation.
As our data suggests that NEAT1 overexpression favours a
chromatin landscape for active transcription, we investigated
whether NEAT1 could directly interact with nucleosomal
histones. Nuclear lysates from VCaP cells were used in an
immunoprecipitation experiment with streptavidin beads coupled
with either scrambled, antisense NEAT1, or antisense NR_024490
(another ERa lncRNA target) oligonucleotides. NEAT1 was
found to speciﬁcally associate with histone H3 (Fig. 5e, left panel,
lane 8) and the speciﬁcity of this binding is apparent when
comparing lanes 7 and 9, which represent Streptavidin-IP using
scrambled biotinylated oligos and Streptavidin-IP using anti-
sense-NEAT1 oligos and nuclear lysates from NEAT1 siRNA-
treated cells, respectively. As an additional negative control, we
used scrambled and speciﬁc antisense oligos for a different
lncRNA, NR_024490, another ERa target. The results indicate
that NEAT1 can associate with chromatin via a speciﬁc
interaction with histone H3. We also determined association of
NEAT1 with active histone H3 modiﬁcations, including H3AcK9
and H3K4Me3 (Fig. 5e, right panel). Similar association patterns
were seen for NEAT1 in NCI-H660 cells (Supplementary Fig. 4b).
To complement this ﬁnding, we performed RNA immunopre-
cipitation from VCaP ERa cells using anti-histone H3 and anti
SNRNP70 (positive control) as the immunoprecipitating anti-
body. qRT–PCR showed robust binding of NEAT1 to histone H3
(Supplementary Fig. 4c). The positive control U1 small nuclear
RNA showed high enrichment in the immunoprecipitate with
SNRNP70. To further conﬁrm the speciﬁcity of NEAT1 binding
to histone H3, we performed a streptavidin–biotin pull-down
assay in VCaP and VCaP ERa cells with and without E2
(Supplementary Fig. 4d). These data suggest that NEAT1 can
directly interact with the histone H3 component of chromatin.
NEAT1 promotes prostate tumorigenesis. To better understand
the physiological role of NEAT1 in the context of ERa in prostate
cancer, we ﬁrst determined the levels of NEAT1 in VCaP cells
overexpressing ERa (Supplementary Fig. 5a). Further, we gener-
ated stable VCaP and VCaP ERa cell lines that overexpress
NEAT1 (Supplementary Fig. 5b). We also knocked down NEAT1
in VCaP and VCaP ERa-expressing cells by stably expressing
NEAT1 shRNA targeting two different regions of NEAT1 and
non-targeting shRNA (Supplementary Fig. 5c). Although over-
expression of NEAT1 signiﬁcantly increased proliferation and cell
invasion, knockdown of NEAT1 signiﬁcantly decreased pro-
liferation and the invasive properties of the cells (Fig. 6a,b).
Soft agar assays were performed in both VCaP and VCaP
NEAT1 cells. Colonies were monitored over a period of 21 days.
Overexpression of NEAT1 resulted in a signiﬁcantly higher
number of viable colonies (Fig. 6c). Colony-forming assays
performed in NEAT1 clones in VCaP cells with and without E2
demonstrated that E2 treatment in NEAT1-overexpressing cells
signiﬁcantly increased the number of colonies (Fig. 6d). These
in vitro assays establish an oncogenic role for NEAT1.
To further validate the oncogenic role of NEAT1, we extended
our studies to an in vivo model system. We performed xenograft
studies in NOD-SCID mice. The mice were treated with time-
release oestrogen pellets. They were divided into two groups and
one group was implanted subcutaneously with VCaP ERa cells
expressing control shRNA luciferase reporter, and the other
group with VCaP ERa cells expressing NEAT1 shRNA luciferase
reporter. The mice from both groups were imaged weekly for
luciferase activity and Fig. 6e shows the bioluminescent signals at
day 7 and day 35. The tumour growth was monitored weekly for
45 days and was found to be signiﬁcantly lower in the NEAT1
shRNA-expressing group compared with the control group
(Fig. 6f). The tumours were excised and weighed, and the
NEAT1 shRNA group had signiﬁcantly smaller tumours
(Supplementary Fig. 6a,b). We conﬁrmed the efﬁcacy of the
shRNA in vivo by measuring the NEAT1 and ERa levels in the
tumours (Supplementary Fig. 6c).
To further substantiate our hypothesis that NEAT1 plays a role
in tumorigenesis, we repeated the experiment in athymic nude
mice using VCaP control and VCaP NEAT1-overexpressing cells,
as well as NCI-H660 and NCI-H660 NEAT1-overexpressing cells.
In both these experiments, a signiﬁcantly higher tumour growth
was seen in the NEAT1-overexpressing cells (Fig. 6g,h and
Supplementary Fig. 6d,e) further conﬁrming its oncogenic
potential. qRT–PCR analysis conﬁrmed an increased expression
of the NEAT1 signature genes in VCaP NEAT1 xenografts
compared with control VCaP xenograft tissue (Supplementary
Fig. 6f).
NEAT1 is associated with therapeutic resistance. The study
presented so far shows that ERa establishes an oncogenic cascade
and that NEAT1 functions as a downstream mediator of ERa
signalling. The ERa-NEAT1 axis is functional both in AR-posi-
tive and -negative cell lines, and drives prostate carcinogenesis.
We hypothesized that targeting NEAT1 using mechanisms that
can constrain ERa might represent a novel therapeutic strategy in
prostate tumours that are resistant to anti-androgen therapy. To
test this hypothesis in vitro, we evaluated the effect of anti-oes-
trogens and anti-androgens on NEAT1 levels in prostate cancer
cell lines. As shown in Fig. 7a,b, NEAT1 expression is constrained
when cells are treated with the ERa antagonists ICI 182,780 (ICI)
and 4-hydroxy tamoxifen (4OHT) in combination with E2.
Intriguingly, treatment of ICI and 4OHT alone for longer periods
can enhance NEAT1 expression (Fig. 7a,b). We observed similar
results with AR antagonists enzalutamide and bicalutamide
(Fig. 7c,d). These results provide compelling evidence to evaluate
NEAT1 levels in advanced CRPC cases. RNA-ﬂuorescent ISH
analysis of benign and advanced prostate tumours, including
CRPC and NEPC tumour tissue samples, illustrated signiﬁcantly
upregulated NEAT1 levels in advanced prostate cancer, with
enhanced focal staining throughout the tumour tissue (Fig. 7e).
We also screened nine cases of benign prostate, seven PCa and
seven CRPC (Supplementary Table 2) for NEAT1 and ERa
expression by qRT-PCR (Fig. 7f), and both NEAT1 and ERa
levels were signiﬁcantly higher in the CRPCs. We determined the
correlation between NEAT1 and ERa expression by estimating
the Pearson’s correlation coefﬁcient R. The results indicate a
strong positive correlation: R¼ 0.86 (P-value¼ 1.9e 07). Taken
together, our results present a novel role for the non-coding
transcriptome in cancer-favourable adaptations.
NEAT1 is associated with aggressive prostate cancer. Given the
importance of NEAT1 in promoting tumorigenesis both in vitro
and in vivo, we sought to determine the relationship between
NEAT1 levels and prostate cancer clinical outcomes in 594
patients from two radical prostatectomy cohorts with long-term
clinical follow-up from the Mayo Clinic35,36. Supplementary
Table 1 contains the patient characteristics of men who
underwent radical prostatectomy at the Mayo Clinic
Comprehensive Cancer Center between 1987 and 2001 for
clinically localized prostate cancer.
We assessed the prognostic potential of NEAT1 expression
using several statistical measures and correlating it with
biochemical recurrence (BCR) and metastasis (MET), prostate
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cancer-speciﬁc mortality (PCSM) and GS47. To evaluate
endpoints of disease aggressiveness and progression based on
NEAT1 expression, Kaplan–Meier (KM) analysis was performed
for the BCR and MET endpoints. The resulting KM curves
(Fig. 8a,b) demonstrate that patients with higher NEAT1
expression have signiﬁcantly worse outcomes for both BCR
(P-value: 0.028) and MET events (P-value: 0.016).
Patient risk discrimination based on the expression proﬁle of
NEAT1 was assessed by area under the receiver operating
characteristic curve with 95% conﬁdence intervals (Supplementary
Fig. 7). NEAT1 signiﬁcantly segregates patients who exhibited BCR,
MET, PCSM and GS47.
To further compare NEAT1’s prognostic ability to other clinic-
opathologic variables, univariable odds ratios were computed for
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Figure 6 | NEAT1 is a driver of oncogenic cascade. (a) Cell proliferation assays were performed in VCaP vector control, NEAT1-overexpressing cells and
also in si scrambled and NEAT1 knockout cells with or without E2 treatment (10 nM) at 24 and 48 h time points. Results are expressed as the mean±s.d.
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statistically signiﬁcant. (b) Quantitative bar chart for depicting percentage of cells invaded at the completion of invasion assays performed in VCaP vector
control, NEAT1-overexpressing cells and also in si scrambled and NEAT1 knockout cells with or without E2 treatment (10 nM). Results are expressed as the
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with or without E2 treatment (10 nM). The right panel depicts the number of colonies at 21 days. Results are expressed as the mean±s.d. calculated from
three independent experiments. *Po0.05 and **Po0.01, Student’s t-test. (e) VCaP ERa cells expressing con shRNA luciferase (luc) and NEAT1 shRNA luc
were injected subcutaneously into the ﬂank of male NOD-SCID mouse. Bioluminescent imaging on Day 7 and Day 35 in the VCaP ERa scrambled shRNA
(top panel) and VCaP ERa NEAT1 shRNA (bottom panel) injected mice is shown. (f) Growth curve for the tumours monitored upto 45 days. Results are
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the BCR, MET, PCSM and GS47 endpoints (Fig. 9). NEAT1 was
signiﬁcantly prognostic for segregating high-risk from low-risk
patients for each of the endpoints (Po0.05). Further multivariate
analysis adjusting for adjuvant radiation and hormone treatment,
in addition to the other clinicopathological variables assessed, also
demonstrates that NEAT1 was signiﬁcantly prognostic for BCR,
MET and GS47, supporting NEAT1 as a prognostic biomarker
for aggressive prostate cancer independent of common clinical
and pathologic variables (Supplementary Fig. 8). Overall, these
results show that NEAT1 is signiﬁcantly prognostic for several
clinically relevant endpoints.
Discussion
The tissue-speciﬁc role of ERa in breast and other gynaecological
malignancies is well understood. Interestingly, ERa is expressed
in all prostate cancers, including those that lack AR expression,
while it is absent in normal prostate epithelium. Studies from our
and other laboratories have examined the relevance of ERa in
prostate cancer4,50–52. ERa-mediated regulation of oncogenic
TMPRSS2-ERG fusion and oestrogen regulation of the EBAG9
gene, which conﬁrms aggressive behaviour of prostate cancer, are
noted examples that suggest a functional ERa-signalling pathway
exists in prostate cancer. From a clinical perspective, the
association of a polymorphism in ERa with prostate cancer
with a favourable GS or cancers of late onset has also been
reported53. These initial observations prompted us to evaluate
whether re-expression of ERa and the establishment of an
alternate nuclear receptor-signalling axis (that is, ERa versus AR)
in prostate cancer cells could represent an adaptive mechanism to
evade AR-directed therapies.
Analysis of global ERa recruitment in prostate cancer cells
using a ChIP-seq approach revealed that ERa is preferentially
recruited to intergenic regions of the prostate genome. Compar-
ison of binding proﬁles with transcriptome sequencing data
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suggested that ERa drives expression of non-coding transcripts.
These results led us to analyse the functional consequences of
ERa recruitment to non-coding regions. From a large compen-
dium of ERa-regulated non-coding transcripts, we selected
NEAT1 for a detailed biochemical and in vivo evaluation, based
on an in silico approach that demonstrated a strong association of
NEAT1 with prostate cancer progression. We show that ERa
transcriptionally regulates NEAT1. NEAT1 is recruited to the
promoter of several key target genes and induces an active
chromatin state favourable for transcription. Our studies indicate
that ERa does not function as a molecular chaperone to guide
NEAT1 to target chromatin; rather, we suspect that a complex
proteome of chromatin-interacting proteins interacts with and
guides NEAT1 to promoter targets. Interestingly, both ERa and
NEAT1 signalling were refractory to AR inhibitors and the lack of
AR or ERb, thus indicating a functional specialization of the ERa-
NEAT1 axis for prostate cancer progression. Furthermore,
introduction of cells overexpressing NEAT1 could clearly induce
prostate cancer progression in experimental animal models.
The current study opens up a new arena of alternative
mechanisms of tumorigenesis by ERa in prostate cancer. We
show that ERa regulates NEAT1 lncRNA with distinct chromatin
regulatory functions. Large-scale bioinformatic analysis of SAGE
libraries has identiﬁed NEAT1 as one of the differentially
regulated lncRNAs between some types of cancer and normal
tissue54. However, its possible role in promoting tumorigenesis
has never been explored. We show here that NEAT1 regulates
expression of prostate cancer genes by altering the epigenetic
landscape at target gene promoters to favour transcription.
A closer examination of NEAT1 revealed a previously
uncharacterized role in recognition of modiﬁed histones. We
have not tested whether NEAT1 is a reader of multiple histone
H3 post-translational modiﬁcations (acetylation, methylation and
so on) and our laboratory is actively pursuing this intriguing
question. NEAT1 expression independently was sufﬁcient to
activate prostate cancer genes in an AR-independent manner.
Further, our results conﬁrmed an oncogenic role for NEAT1 in
an experimental animal model of prostate cancer and in cell
culture models.
Molecular sieving of the net non-coding transcriptome using
comprehensive bioinformatic approaches and wet-lab validation
over a decade has indicated that the non-coding transcriptome has
a regulatory role beyond the speculated ‘transcriptional noise’ and
a direct inﬂuence on the coding transcriptome and biologic
homeostasis. We observed that several lncRNAs such as NEAT1
respond to cellular cues and ligand signalling in a manner
reminiscent of the coding transcriptome. Thus far, the literature on
NEAT1 has focused on its architectural role in forming subnuclear
paraspeckles27. Our results indicate a role for NEAT1 beyond that
of paraspeckles. It would be interesting in the future to reconcile
how the formation of paraspeckles in the inter-chromosomal space
ties in with the role of NEAT1 in activating gene expression at
promoters. Our lab continues to pursue some of these unanswered
questions to better understand the role of NEAT1.
Our identiﬁcation of an ERa-NEAT1 axis illustrates a
mechanism whereby prostate cancer cells may develop therapeu-
tic resistance through positive selection of an alternate nuclear
receptor signalling pathway in the absence of AR or during
androgen ablation therapy (Fig. 10). However, we cannot exclude
the presence of other NEAT1-interacting chromatin factors. This
is the subject of ongoing investigation.
From a clinical perspective, our studies indicate for the ﬁrst
time that NEAT1 is signiﬁcantly prognostic for several clinically
relevant endpoints. In prostatectomy specimens from two large
cohorts, high NEAT1 expression was associated with a signiﬁcant
increase in both biochemical and metastatic recurrence rates
compared to those with low NEAT1 expression.
In summary, this study provides important insights into a
unique mechanism of ERa regulation in prostate cancer and
identiﬁes NEAT1 as a novel prognostic marker and potential
therapeutic target in this disease. Although our studies have
identiﬁed a previously unexplored function of ERa in regulating
lncRNAs, it is also the ﬁrst of its kind to demonstrate
transcriptional regulation of lncRNAs by an alternative steroid
receptor in prostate cancer. We propose that NEAT1 is directly
involved in modulation of the phenotype of a leading disease.
Combinatorial targeting of NEAT1 and AR may represent a
unique therapeutic regimen within a subset of patients with
advanced prostate cancer.
Methods
Cell culture and treatments. LnCaP and PC3 cells were grown in RPMI 1640
(Invitrogen) and supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin–streptomycin. RWPE1 cells were grown in Keratinocyte Serum Free
Medium Kit (Gibco, 17005-042). VCaP and DU145 cells were grown in DMEM
(Invitrogen) and supplemented with 10% FBS with 1% penicillin–streptomycin.
NCI-H660 cells were grown in RPMI 1640 supplemented with 0.005mgml 1
insulin, 0.01mgml 1 transferrin, 30 nM sodium selenite, 10 nM hydrocortisone,
10 nM b-estradiol, 5% FBS, 1% penicillin–streptomycin and an extra 2mM of
L-glutamine (for a ﬁnal concentration of 4mM). For cell treatments in several
experiments, we used 10–100 nM b-estradiol (Sigma Aldrich, St Louis, MO), 10 mM
Enzalutamide (Astellas), 10 mM bicalutamide (Sigma Aldrich), 1–10 nM R1881
(PE Biosystems), 10–100 nM 4OHT (Sigma Aldrich) and 1–10 mM ICI (Tocris
Bioscience).
Plasmids, siRNAs and transfection. Plasmids, pcDNA 3.1, pcDNA3.1-ERa,
pcDNA 3.1 AR, piLenti-GFP, piLenti-NEAT1 siRNA-GFP (set of four, sequences
provided in Supplementary Table 3), iLenti-si-scrambled, pLenti-bicistronic-luc-
NEAT1 were used. siRNAs for ERa, ERb, AR, NEAT1 and NEAT1_2 were used,
and the sequence is provided in Supplementary Table 3. For the mammalian
expression vectors, Lipofectamine 3000 (Invitrogen) and Lonza nucleofection were
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Figure 9 | NEAT1 is a strong prognosticator of prostate cancer. (a–d)
Univariable forest plots comparing the expression of NEAT1’s short
(NEAT1_1) and long isoform (NEAT1_2) to clinicopathologic variables in the
pooled Mayo cohort (n¼ 594) (a) BCR, (b) MET, (c) PCSM and (d) GS47.
Pathological tumour stage 3 or greater (pT3þ ), lymph node invasion (LNI),
surgical margin status (SMS) positive, seminal vesicle invasion (SVI), extra
capsular extension (ECE), preoperative PSA (pPSA), adjuvant hormone
therapy and adjuvant radiation therapy are shown.
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used for transfection. The stable clones for NEAT1 overexpression as well as the
scrambled and NEAT1 shRNA-expressing cells were generated by using the len-
tiviral vectors and by selection in puromycin.
Identiﬁcation of ERa-regulated lncRNA. A set of known lncRNAs was generated
from various data sources: RefSeq: GENCODE v7, - ncRNA.org and lncRNAdb55
(see Supplementary Material) and those that were at least 200 nt long were selected,
resulting in 12,483 lncRNAs. These lncRNAs were characterized according to their
potential of being regulated by ERa by using ERa-binding sites information from
ChIP-seq experimental data. Moreover, several histone marks were considered to
provide evidence of transcription, including H3K4me3 and H3K36me3 (details in
Supplementary Material).
Differential expression analysis. To prioritize the experimental validation of
lncRNAs, a pair-wise differential expression analysis was performed on the
expression values determined by paired-end transcriptome sequencing of 73
samples (26 benign prostate, 40 PCa and 7 NEPC). A pair-wise Wilcoxon test was
performed and all P-values were corrected for multiple hypotheses testing using
Benjamini–Hochberg56 (details in Supplementary Material).
ERa and NEAT1 signature via Oncomine concept analysis. RNA sequencing
was done for VCaP and VCaP ERa-expressing cells, as well as in vector control and
NEAT1-overexpressing VCaP cells (detailed in Supplementary Methods). The
expression of the genes was computed and those genes with a log2-fold change42
were selected. Results are reported in Supplementary Datasets 3 and 5. Five hun-
dred and eighty-eight genes were found to be overexpressed in VCaP ERa cells. A
custom concept of this gene list was generated in Oncomine (Supplementary
Dataset 4). Similarly, genes from the VCaP NEAT1 group with a log2-fold change
42 were selected and a custom concept was built in Oncomine using the top 1,000
genes from NEAT1 signature (Supplementary Dataset 4). The signiﬁcantly asso-
ciated tumour versus normal concepts with odds ratio 42.0 and Po1 10 6
considering tumour versus normal analysis was determined. The resulting concepts
and associations are represented through a concept network using Cytoscape
version 2.8.2. Each node represents a concept to which the signature is associated at
a 43-fold odds ratio for ERa signature and 42-fold odds ratio for NEAT1
signature. Node size reﬂects the concept size, that is, the number of genes in each
concept; red and green colours represent correlation with over- or underexpressed
genes in the concept, respectively; and edge thickness represents the odds ratio of
the association between concepts, ranging from 1.4 to 29.9 and 1.2 to 637 for ERa
and NEAT1 signatures, respectively. The border colour of each node represents the
tumour type. The layout of the network is based on the Edge-weighted spring-
embedded algorithm.
Luciferase reporter assays. For ERE luciferase assays, VCaP cells were transiently
transfected with the (ERE)3-SV40-luc reporter plasmid and/or ERa and/or AR, as
well as an internal control construct pRL harbouring the renilla luciferase gene.
VCaP cells were also transfected with empty vector or NEAT1 promoter (1þ 2)
luciferase reporter constructs alone or with ERa, as well as an internal control
construct pRL harbouring renilla luciferase gene. To determine the PSMA reporter
activity, 293T and PC3 cells were co-transfected with empty vector or PSMA luc
and Renilla-luc reporter genes alone or with NEAT1, NEAT1þERa or
NEAT1þAR.
Twenty-four hours post transfection, the media was changed to 5% charcoal-
stripped media and the cells indicated were treated with E2 (10 nM) or R1881
(1 nM) for 14 h. At 48 h, cells were lysed with passive lysis buffer and luciferase
activities were measured using the dual luciferase system (E1910, Promega) and
normalized with renilla luciferase activity.
RNA ISH for NEAT1. RNA ISH for NEAT1 was performed on ﬁve benign, ﬁve
PCa and three CRPC cases using kits and probes designed by Advanced Cell
Diagnostics. Brieﬂy, the single-colour chromogenic detection assay uses pairs of
specially designed oligonucleotide probes that through sequence-speciﬁc hybridi-
zation, recognize both the speciﬁc target NEAT1 RNA sequence and the signal
ampliﬁcation system. Unique target probe oligonucleotides were designed to
hybridize in tandem to the target RNA. Cross-hybridization to other sequences is
minimized by screening against the entire human RNA sequence database.
The signal ampliﬁcation system consists of the pre-ampliﬁer, ampliﬁer and
enzyme-conjugated label probe, which assemble into a tree-like complex through
sequential hybridization. Signal ampliﬁcation occurs at target sites bound by probe
pairs only. Nonspeciﬁc off-target binding by single probes does not result in signal
ampliﬁcation.
All steps of NEAT1 RNA ISH staining of the slides are performed manually,
optimized in tissue microarrays. Brieﬂy, formalin-ﬁxed, parafﬁn-embedded
unstained tissue sections (5mm) were mounted on positively charged microscopic
glass slides, deparafﬁnized in xylene and rehydrated through a series of alcohols. The
rehydrated sections were treated with 3% hydrogen peroxide at room temperature
(RT) for 10min to block endogenous peroxidase. Sections were then boiled in 1
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citric buffer (10 nmol l 1 Nacitrate, pH 6.0) for 15min and incubated with protease
(2.5mgml 1; Sigma Aldrich) at 40 C for 30min. The slides were hybridized
sequentially with target probes (20 nmol l 1) in hybridization buffer A (6 saline
sodium citrate (SSC) buffer (1 SSC is 0.15mol l 1 NaCl and 0.015mol l 1 Na-
citrate), 25% formamide, 0.2% lithium dodecyl sulfate (LDS) and blocking reagents)
at 40 C for 2 h, signal pre-ampliﬁer in hybridization buffer B (20% formamide,
5 SSC, 0.3% LDS, 10% dextran sulfate and blocking reagents) at 40 C for 30min,
ampliﬁer in hybridization buffer B at 40 C for 30min and horseradish peroxidase-
or alkaline phosphatase-labelled probes in hybridization buffer C (5 SSC, 0.3%
LDS and blocking reagents) at 40 C for 15min.
Hybridization signals were detected under bright-ﬁeld microscope as red
colorimetric staining (using Fast Red chromogen, BioCare Biomedical, Concord,
CA) followed by counterstaining with haematoxylin. Signals were granular and
discrete red signals corresponding to individual lncRNA targets. The signals were
scored using the RNA Spot Studio software.
Chromatin immunoprecipitation. All ChIP experiments were carried out using
Millipore EZ-Magna ChIP kit (catalogue number 17–10086). Brieﬂy, 5–10 106 cells
were cross-linked with 1% formaldehyde for 10min at rRT. The cross-linking was
then quenched with 0.125M glycine. Chromatin was sonicated in the lysis buffer to
300–500 bp and the extraction of ChIP DNA was done as per the kit protocol.
Antibodies used include ERa (AC-066-100, diagenode, 5mg), AR (06–680, Millipore,
5mg), H3K4me3 (ab8580, Abcam, 5mg), trimethylated lysine 9 of histone H3
(ab8898, Abcam, 5mg), H3K36me3 (ab9050, Abcam, 5mg), trimethylated lysine 27 of
histone H3 (07–449, Millipore, 5mg) and Ace-H3 (no. 06–599, Millipore, 5mg).
ERa ChIP was also performed in cross-linked VCaP cells with E2 treatment for
0, 14 and 48 h. In VCaP ERa cells, E2 treatment was for 6, 14 and 48 h. The primer
sequences are provided in Supplementary Table 4.
Chromatin isolation by RNA puriﬁcation. ChIP for NEAT1 was done in VCaP
control and NEAT1-expressing cells, with and without E2 treatment using the
ChiRP protocol45. Brieﬂy, biotin TEG antisense oligos were generated using
singlemoleculeﬁsh.com for NEAT1, Lac Z and scrambled NT NEAT1. The NEAT1
probes were divided into two pools. Cells cross-linked in 1% glutaraldehyde were
lysed and sonicated. The biotinylated probes were hybridized followed by RNA and
DNA isolation. qPCR was performed on the DNA samples. Probe sequences are
described in Supplementary Table 5.
RNA ISH for NEAT1 on cell lines. Cells were grown on a 15mm, poly-L-lysine-
coated glass coverslip. At B70% conﬂuence, cells were serum starved in 8%
charcoal-stripped media for 48 h, followed by 48 h treatment with 10 nM E2. At the
end of treatment, cells were ﬁxed in 4% formaldehyde, dehydrated by an ethanol
gradient (50–100%) and stored at  20 C. For the hybridization assay, cells were
rehydrated by an ethanol gradient (100–50%) into PBS. Between subsequent steps,
cells were washed with PBS. The Affymetrix QuantiGene ViewRNA ISH cell assay
kit was used for NEAT1 staining. Cells were permeabilized by 5min incubation at
RT in Detergent Solution QC and digested for 10min at RT by Protease QS
(1:4,000 in PBS). Next, the target-speciﬁc Probe Set (1:100 in Diluent QF) was
allowed to hybridize for 3 h at 40±1 C. Between subsequent steps, cells were
washed by soaking in Wash Buffer. Sequential hybridization steps were conducted
for signal ampliﬁcation—PreAmpliﬁer Mix (1:25 in Diluent QF), Ampliﬁer Mix
(1:25 in Diluent QF) and Label Probe Mix (1:25 in Diluent QF), each incubated
30min at 40±1 C. After two 10-min washes in Wash Buffer, nuclei were stained
with 40,6-diamidino-2-phenylindole and cover slips were mounted to slides with
Prolong Gold Antifade Reagent (Life Technologies) for visualization.
Proliferation assay. Cell proliferation was assessed using the CyQUANT NF cell
proliferation assay kit (Life Technology). Cells were seeded in 96-well plates at 3–
4 104 cells per well. Cells were incubated in DMEM media with 10% FBS for 24 h.
The cells were then serum starved in 8% charcoal-stripped DMEM medium for
48 h followed by E2 treatment at 10 nM concentration for indicated time points.
The media was then aspirated and replaced with the dye-binding solution followed
by incubation for 30–60min. The ﬂuorescence was then measured in a microplate
reader using excitation at 485±10 nm and ﬂuorescence detection at 530±15 nm.
The assay was performed in triplicates.
Invasion assay. The CHEMICON cell invasion assay kit (EMD MIlipore) was used
for determining the cell invasion. Cells were serum-starved for 48 h and then seeded
at a density of 2 105 cells per well in the upper well of the invasion chamber. Five
hundred microlitres of phenol red-free DMEM media supplemented with 8%
charcoal-stripped serum and 10nM E2 was added to the lower chamber. After 48-h
incubation, the invaded cells were stained by dipping the inserts in the staining
solution for 20min. The stained cells were then dissolved in 10% acetic acid and
transferred to a 96-well plate for colorimetric reading of optical density at 560nm.
Migration assay. The Cell Biolabs Inc. Radius 96-Well Cell Migration Assay was
used to determine cell migration. Cells were serum starved for 48 h, then seeded to
a pretreated (incubated 20min in Radius Gel Pretreatment solution and washed
with Radius Wash Solution) Radius 96-Well Plate at a density of 8 104 cells per
well with or without E2 (10 nM). After 24 h incubation, the Radius Gel Spot was
removed via the Radius Gel Removal Solution and pre-migration images were
captured. After 24-h incubation, cells were stained with Cell Stain Solution and
post-migration images were captured for analysis using the CellProﬁler Cell Image
Analysis Software (Broad Institute).
Statistical analysis. The Wilcoxon test was employed with Benjamini–
Hochberg56 correction for multiple hypotheses for pair-wise comparisons for
differential expression analysis. The w2-test was used for comparison of proportions
and the Pearson’s correlation was used to compare the expression of selected genes.
For qRT–PCR, we computed the Delta CT value according to the ABI qPCR
guidelines as described in Supplementary Methods. To compare qPCR data, a
Student’s t-test was employed. Median rank statistics results are reported for
analyses with the Oncomine data sets57.
Analysis of Mayo clinic cohort. Affymetrix HuEx microarrays were used to
analyse NEAT1 expression in two post-radical prostatectomy cohorts from the Mayo
Clinic. Details on tissue preparation, RNA extraction, ampliﬁcation, hybridization
and clinical characteristics for these cohorts have been described previously35,36.
Both cohorts were ﬁltered using the same criteria (patient either exhibiting pre-
operative prostate-speciﬁc antigen 420ngml 1, GS Z8, pT3b or GPSM58 score
Z10) to increase the homogeneity of patient characteristics. The two sets were
pooled to improve analytic power, resulting in a data set of 594 patients. The patient
characteristics of the pooled data set can be found in Supplementary Table 1.
A representative Probe Selection Region for the genomic span of the short and
long NEAT1 isoforms was selected by minimizing the technical variance across the
pooled data set. Based on these two Probe Selection Regions, the prognostic
performance of NEAT1 short and long isoforms was evaluated using univariable
and multivariable odds ratios, and area under the receiver operating characteristics
curve for BCR, MET, PCSM and GS47 endpoints. KM curves were used to
perform survival analysis on the Mayo case–cohort patients only35, as the nested
case–control cohort58 was not suitable for KM analysis.
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